Back Number
2022
- October 31 " Financial Results " was updated.
- September 16 Positive Top-line Results of Phase 3 Clinical Study (Comparative Study) of JTE-061 (tapinarof) Cream, Aryl Hydrocarbon Receptor (AhR) Agonist, in Patients with Plaque Psoriasis in Japan（PDF）
- July 29 " Financial Results " was updated.
- July 20 Top-line Results of Phase 3 Clinical Study (Comparative Study) of JTE-061 (tapinarof) Cream, Aryl hydrocarbon Receptor (AhR) agonist, in Adult and Adolescent Patients with Atopic Dermatitis in Japan（PDF）
- June 16 " Annual Report " was updated.
- April 28 " Financial Results " was updated.
- March 14 Torii’s Views on Report from ISS, a Proxy Advisory Firm, On Proposals for Torii’s General Meeting of Shareholders（PDF）
- March 8 " NOTICE OF THE 130th ANNUAL GENERAL MEETING OF SHAREHOLDERS（PDF） " was updated.
- February 18 Notice of the Opinion of the Board of Directors Regarding the Shareholder Proposal（PDF）
- February 10 " Financial Results " was updated.
- February 10 Torii has announced New Corporate Philosophy, Medium-/Long-Term Business Vision, and Medium-Term Management Plan 2022-2024（PDF）
2021
- December 14 Top-line Results of Phase 3 Clinical Study of JTE-052 Ointment, JAK Inhibitor, in Infant Patients with Atopic Dermatitis in Japan（PDF）
- October 29 " Financial Results " was updated.
- July 30 " Financial Results " was updated.
- June 9 " Annual Report " was updated.
- May 26 Listing on the Japanese National Health Insurance Drug Price List and Launch of CORECTIM® Ointment 0.25% in Japan（PDF）
- April 28 " Financial Results " was updated.
- April 21 Listing on the Japanese National Health Insurance Drug Price List and Launch of ORLADEYO Capsules 150mg for Suppression of HAE Attacks in Japan（PDF）
- March 23 JT Receives Approvals of CORECTIM® Ointment 0.25% and CORECTIM® Ointment 0.5% for the Treatment of Pediatric Atopic Dermatitis in Japan（PDF）
- March 23 JT Receives Approval for Additional Indication for Iron Deficiency Anemia for Riona® and Promotion to Start in Japan（PDF）
- March 17 Torii has entered into License Agreement with Verrica Pharmaceuticals to Develop & Commercialize VP-102 in Japan（PDF）
- February 4 " Financial Results " was updated.
- January 22 OrphanPacific Inc.Receives Manufacturing and Marketing Approval of ORLADEYOCapsules150mg for Suppression of HAE Attacksin Japan（PDF）
2020
- November 18 Listing on the Japanese National Health Insurance Drug Price List and Launch of ENAROY® Tablets 2mg･4mg for the Treatment of Anemia Associated with Chronic Kidney Disease in Japan（PDF）
- October 30 " Financial Results " was updated.
- September 25 JT Receives Manufacturing and Marketing Approval of ENAROY® Tablets 2mg・4mg for the Treatment of Anemia Associated with Chronic Kidney Disease in Japan（PDF）
- August 5 Torii has entered into Option Agreement with Verrica Pharmaceuticals to Develop & Commercialize VP-102 in Japan（PDF）
- July 31 " Financial Results " was updated.
- June 30 " Annual Report " was updated.
- June 1 Torii and ASKA Enter into Co-Promotion Agreement Concerning Additional Indication of Iron Deficiency Anemia for Riona®（PDF）
- May 29 JT Files New Drug Application of JTE-052 Ointment, JAK inhibitor, for the Treatment of Pediatric Atopic Dermatitis in Japan（PDF）
- May 15 JT Files for Additional Indication for Riona®, Ferric Citrate Hydrate, for Iron Deficiency Anemia in Japan（PDF）
- April 30 " Financial Results " was updated.
- April 22 Listing on the NHI Drug Price List and Launch of CORECTIM® Ointment 0.5% for the Treatment of Atopic Dermatitis in Japan（PDF）
- March 18 Company Spin-Off (Short-Form Absorption-Type Company Split) and Share Transfer of a Newly Founded Subsidiary with Transfer of Sakura Plant（PDF）
- February 6 " Financial Results " was updated.
- February 6 Progress of the Medium-Term Management Plan 2021 and Revision of the Targets（PDF）
- January 23 JT Receives Manufacturing and Marketing Approval of CORECTIM® Ointment 0.5% for the Treatment of Atopic Dermatitis in Japan（PDF）
- January 15 Torii Signs Exclusive License Agreement with JT for Development and Commercialization of Tapinarof in Japan（PDF）